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Background: An imaging tool providing reliable prostate cancer (PCa) detection and localization is necessary to
improve common diagnostic pathway with ultrasound targeted biopsies. To determine the performance of
transrectal ultrasound (TRUS) augmented by prostate HistoScanningTM analysis (PHS) we investigated the detection
of prostate cancer (PCa) foci in repeat prostate biopsies (Bx).
Methods: 97 men with a mean age of 66.2 (44 – 82) years underwent PHS augmented TRUS analysis prior to a
repeat Bx. Three PHS positive foci were defined in accordance with 6 bilateral prostatic sectors. Targeted Bx (tBx)
limited to PHS positive foci and a systematic 14-core backup Bx (sBx) were taken. Results were correlated to biopsy
outcome. Sensitivity, specificity, predictive accuracy, negative predictive value (NPV) and positive predictive value
(PPV) were calculated.
Results: PCa was found in 31 of 97 (32 %) patients. Detection rate in tBx was significantly higher (p < .001).
Detection rate in tBx and sBx did not differ on patient level(p ≥ 0.7). PHS sensitivity, specificity, predictive accuracy,
PPV and NPV were 45 %, 83 %, 80 %, 19 % and 95 %, respectively.
Conclusions: PHS augmented TRUS identifies abnormal prostatic tissue. Although sensitivity and PPV for PCa are
low, PHS information facilitates Bx targeting to vulnerable foci and results in a higher cancer detection rate. PHS
targeted Bx should be considered in patients at persistent risk of PCa.
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Transrectal ultrasound (TRUS) imaging and systematic
TRUS-guided biopsies (Bx) are gold standard procedures
for prostate diagnostics and detection of prostate cancer
(PCa) [1, 2]. However, the power to identify - and in par-
ticular to exclude - cancer reliably is limited due to low
PCa specificity of grey scale ultrasound patterns [3]. Up
to one-third of men with an initial negative systematic
Bx are found to have prostate cancer in subsequent Bx
[3, 4]. The question whether to pursue further repeat
TRUS guided Bx in patients with a rising prostate-
specific antigen (PSA) level subsequent to an initially* Correspondence: moritz.hamann@uksh.de
Department of Urology and Pediatric Urology, University Hospital Schleswig
Holstein, Campus Kiel, Arnold Heller Str. 3, 24105 Kiel, Germany
© 2015 Hamann et al. This is an Open Access
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/negative Bx is a common clinical dilemma and remains
a diagnostic challenge in urology. On the other hand,
multiparametric magnetic resonance imaging (mp MRI)
of the prostate is rapidly gaining significance due to its
capability to detect PCa. Targeted biopsies of suspicious
lesions, using MRI fused with real-time ultrasound, show
encouraging rates of detection of clinically significant
PCa [5]. In contrast to widely-used ultrasound, MRI hard-
ware is expensive and time-consuming diagnostic proto-
cols limit its availability. Further developments in
ultrasound techniques, like contrast enhancement, elasto-
graphy or prostate HistoScanning™ (PHS), improve TRUS
capability to detect pathology confined to the prostatic
gland and increase the validity of TRUS-guided Bx [6].
Initial data on PHS computer-aided ultrasonography havearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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studies is scarce and controversial [8–11].
To generate a greater diagnostic yield than systematic
needle Bx, we integrated the results of HS into our re-
peat prostate biopsy program. We report the cancer de-
tection rate and characteristics of this approach in a
prospective series of 97 consecutive patients with previ-
ous negative prostate Bx.
Methods
At one center, data was collected from 97 consecutive
men with a mean age of 66.2 (44 – 82) years [Table 1].
All of them were at a persistent risk of prostate cancer
and had at least one previous set of TRUS-guided pros-
tate Bx, yielding a non-cancerous diagnosis. All of them
had suspicious findings at the digital rectal examination
(DRE), or serum prostate-specific antigen (PSA) level
>10 ng/mL, or both. Elevated serum PSA levels >4 ng/
mL a PSA-velocity of >0.75 ng/mL p.a. and free-to-total
PSA ratio < 15 % were seen as the indication for prostate
biopsies. Rescanning of the prostate was scheduled at
least three months after the previous manipulation of
the gland in order to minimize impairment of data qual-
ity through earlier diagnostic procedures. All patients
were informed of the mode of the extended prostate Bx
scheme and its potential complications. All patients pro-
vided written informed consent for the procedures. Pa-
tients were advised that information collected from their
Bx would be used for internal analysis and medical re-
search as approved by the local Ethics Committee of the
medical faculty of the University of Schleswig-Holstein,
and was subsequently analyzed retrospectively.
HistoScanning technique and prostate biopsy technique
After indication diagnostics and before starting the Bx
procedure, all patients underwent an automatic stan-
dardized 3-dimensional (3D) transrectal ultrasound
(TRUS) using a BK ProFocus UV ultrasound system
with 8818 tri-plane probe (Analogic Corp, Peabody MA,
USA). To facilitate appropriate data acquisition and a
standardized scanning process, an external motor
sweeps the ultrasound probe's sagittal array. Beside the
signals from macroscopic tissue boundaries, which are
used to create anatomical images, ultrasound produces a
continuous stream of echoes emanating from the tis-
sue`s underlying microscopic features, known asTable 1 Patient characteristics
Mean (range) patient age 66.24 (44–82)
Mean (range) PSA level ng/mL 10.42 (1.02–35.00)
DRE pos / neg (%) 86/11 (89/11)
Prostate volume ml Mean (range) 51.43 (17.00/105.00)
Previous Biopsy sessions Mean (range) 1.46 (1–5)ultrasound backscatter. PHS analyses these backscatter
signals by using numerical descriptors of multipara-
metric measures from the individual 3D raw data scan,
which vary in its properties due to suspicious (malig-
nant) or normal prostatic tissue characteristics. A statis-
tical classifier categorizes corresponding prostatic
regions as normal or suspicious. Displaying these infor-
mations as a colored (red) overlay in the ultrasound im-
ages complements the conventional ultrasound grey-
scale diagnostics.
Computer-aided analysis of the data was performed on
a PHS workstation with software version 2.3 (Advanced
Medical Diagnostics, Waterloo BE). Based on the PHS
image, the physician defined the most prominent (lar-
gest) target regions, up to a maximum of three. In turn,
a structured scaffold was created from PHS projection
reports of the prostate, which was used at a later point
for guidance of targeted Bx procedures (Fig. 1). The lo-
cation of the suspicious/target regions was defined ac-
cording to 12 peripheral sectors and two central sectors:
a bilateral transition zone, apex, center, and base (each
of the latter three medially and laterally).
The biopsy procedures were performed consecutively
during a single visit with the patient in a dorsal lithot-
omy position under general anesthesia. Three targeted
cores were taken transperineally from each suspicious
region based on PHS analysis (maximum of 3). A
brachytherapy template grid fixed to a cradle was placed
next to the perineum and used as a guide. Using the in-
formation from the PHS projection reports, the biopsy
needle was directed through the brachytherapy template
to obtain the Bx under direct TRUS guidance using a
BK 8848 ultrasound probe (Analogic Corp, Peabody
MA, USA). Sampling a target lesion, neither the needle
position (grid perforation) nor the depth of the biopsies
was changed (Fig. 1). Thereafter, three targeted cores
were taken by a transrectal approach from each suspi-
cious region using the tri-plane 8818 probe. Using the
information from PHS analysis, Bx was directed cogni-
tively to the PHS positive volumes. Finally, a standard-
ized 14-core transrectal-guided Bx was performed by
sampling the corresponding seven sectors bilaterally, as
mentioned above. Biopsies were performed randomly by
four senior surgeons with at least five years of biopsy
experience.
The local pathologists of the University Hospital
Schleswig Holstein, Campus Kiel, performed histopath-
ology analysis of Bx cores.
Statistical analysis
All data were registered in a Microsoft Access database
(2010) and tabulated subsequently in Microsoft Excel
(2010), with statistical analysis performed using PC SAS
(Version 9.3 or higher) and R (version 3.0.1). For
Figure 1 HistoScanning report and perineal biopsy setting PHS analysis provides a transversal slice report of the unique prostate showing
suspicious areas with a spatial resolution of 5 mm. The report allows precise and stable constant targeting by the use of an adapted template
grid fixed to a cradle
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A two-sample Chi-squared test of proportions was used
for binomial data. Differences in total PHS suspicious
volume were compared using the Wilcoxon signed rank
test. A p-value of 0.05 was considered to indicate statis-
tical significance.
The cancer detection rate and procedure characteris-
tics for all cases were evaluated. Table 1 summarizes the
patient characteristics.
Results
PHS analysis detected abnormalities in all prostate scans
of the 97 patients included. 224 sectors contained PHS
positive ultrasound patterns. In 31 of 97 (32 %) patients
prostate adenocarcinoma was diagnosed, and 40 of 248
(16 %) sectors harbored cancer with respect to biopsy re-
sults. Additionally, histopathological examination de-
tected atypical small acinar proliferation in seven
patients (7 %), high-grade prostatic intraepithelial neo-
plasia in 20 (21 %) and chronic active inflammation in
72 (74 %) respectively. Based on the combined outcome,diagnostic performance of PHS to detect cancer at sec-
tor level shows sensitivity, specificity, predictive accur-
acy, a positive predictive value (PPV) and a negative
predictive value (NPV) of 45 %, 83 %, 80 %, 19 % and
95 %, respectively. Table 2 summarizes the histological
findings for all patients. The median PHS sum of the
suspicious volume of 3 regions was 1.32 ml (range 0.20-
9.32). Eighty seven patients (90 %) had a PHS sum
≥0.50 ml. Bx outcome and Gleason sum in relation to
PHS suspicious volume is presented in Table 3. With re-
spect to biopsy results, PHS volumes of benign prostate
sectors and prostate sectors harboring cancer did not
differ significantly. In 32 out of 77 (42 %) positive biop-
sies, the cancerous tissue was found in the anterior zone.
34 (44 %) respectively 21 (27 %) cancerous cores were
harvested from the medial and basal parts of the gland.
The occurrence of PHS positive ultrasound patterns did
not differ significantly at sector level. Although the tar-
geted biopsies originated from a maximum of three
prostatic sectors, the detection rate per patient was not
significantly different from systematic Bx. The detection
Table 2 Histopathological results in prostate biopsies
Systematic HS-template targeted transperineal HS- targeted transrectal All biopsies
Bx+ 23 20 21 31
GS sum in Bx+ Mean (range) 6.5 (5–9) 6.5 (5–9) 6.38 (5–9) 6.35 (5–9)
GS sum ≥7 in Bx+ N (%) 5 (5) 10(10) 8(8) 11 (11)
GS I = 2/3 in Bx+ N (%) 19(19) 14(14) 16(16) 24 (25)
GS I = 4/5 in Bx+ N (%) 4(4) 6(6) 5(5) 7 (7)
ASAP N (%) 3(3) 2(2) 2(2) 7 (7)
HG-PIN positive N (%) 12(12) 9(9) 12(12) 20 (21)
Prostatitis N (%) 68(70) 59(61) 59(61) 72 (74)
Bx+, prostate cancer positive biopsy; GS, Gleason Score; ASAP, atypical small acinar proliferations; HG PIN, high-grade intra epithelial proliferations
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in both targeted transperineal and targeted transrectal
Bx compared to systematic Bx(p < .001). Table 4 shows
an analysis of the detection rates of different procedures.
Twenty two cancers were detected by systematic biop-
sies, while 20 and 21 cancers were detected in PHS tar-
geted perineal and transrectal biopsies, respectively. The
detection rate of significant cancer (GS ≥ 7) in PHS-
targeted biopsies was superior in comparison to system-
atic biopsies. Perineal PHS targeted biopsies missed 1
significant cancer, PHS targeted transrectal biopsies
missed 3 significant cancers, respectively. Most of the
cancers (18/23, 78 %) detected by systematic biopsy were
insignificant.
Discussion
Cancer specific accuracy in standard prostate Bx tends to
be determined by PSA, prostate texture recorded by
digital rectal examination as well as the number of biopsy
cores in relation to prostate size, rather than by transrectal
grey scale ultrasound displaying malignant foci [12]. Thus,
a substantial number of patients undergo repeat biopsy,
indicated by weak prognostic factors, still facing the same
limited cancer-specific imaging characteristics of TRUS.
With respect to initial data, PHS seems to overcome these
limitations by analyzing radiofrequency backscattered raw
data of prostatic ultrasound [13]. Our data is unable to
confirm a comparable high prognostic validity for prostate
cancer. In the present study, PHS revealed at least 2 to 3Table 3 Relation between Prostate HistoScanning™ suspicious volum
Total PHS suspicious volume in ml N
median(range)
Total PHS suspicious volume in ml N
median (range)
PHS, prostate HistoScanning; Bx, prostate biopsy; Bx+, prostate cancer positive biop
sum test)aberrations in 94 % and 59 % of the ultrasound scans, but
histopathological analysis confirms malignant tissue in
only 32 % of the patients. Although, these detection re-
sults are within the range of previous studies on repeat bi-
opsies [4], calculations of PHS predictive characteristics
show weak results with respect to PPV (17 %) and sensi-
tivity (44 %). These findings are in line with recent studies
which also failed to show significant accuracy for PHS to
predict positive biopsy results: According to sextant ana-
lysis, PHS had a sensitivity, specificity, PPV and NPV of
32.0-100 %, 5.9-32.7 %, 19.6-22.7 % and 86.4-84 %, re-
spectively [9, 10]. Further analysis found no correlation
between pathology and the whole gland tumor volumes
estimated by PHS, nor between the PHS volumes and
prostate cancer GS [10, 14]. Table 3 shows comparable re-
sults. It has to be taken into account, that PHS algorithms
allow exclusively two opposed classifications (suspicious
vs. non-suspicious) for ultrasound properties in virtual
subvolumes. Based on a repeated but uniform calculation,
the number of decisions as displayed by the PHS volume
does not display varying characteristics or allow risk strati-
fication concerning Gleason grading. Additionally, it must
be assumed that acoustic similarity in the ultrasound
backscatter properties of malignant and nonmalignant
structures might account for further limitations in the
analysis. With respect to specificity and NPV of 83 % and
95 %, respectively, PHS results need careful interpretation
before the results can make a contribution to decision-
making like biopsy indication or planning.e and Bx outcome
Bx + Bx- p-value
31 66
1.58 (0.20-9.32) 1.26 (0.22-6.59) n.s.
Gleason sum <7 Gleason sum > =7
20 11
1.55 (0.20-9.32) 1.86 (0.22-4.35) n.s.
sy; Bx-, prostate cancer negative biopsy; p-values Bx + vs Bx- (Wilcoxon rang
Table 4 Analysis of detection rate per prostate region of different procedures
N = 97 Systematic Bx PHS-template targeted transperineal Bx PHS- targeted transrectal Bx
patients with Bx+ 23 20 n.s. 21 n.s.
regions biopsied 1358 248 248
regions with Bx+ 73 32 28
detection rate per region 5 % 13 % <0.001 11 % <0.001
Biopsy Bx, prostate cancer positive biopsy Bx+, Pca negative biopsy Bx-, p-values compared with systematic biopsy (Chi-squared test)
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improved significantly by PHS-targeted biopsies. On pa-
tient level, the PHS template-targeted biopsies account
for a 27 % increase in the detection rate, transrectal-
targeted biopsies for 23 %, and the combined targeted
biopsies for an increase by 41 % compared to systematic
biopsy alone. PHS perineal targeted biopsies detect
twice as much significant cancer foci than systematic
ultrasound-guided biopsies. De Coninck et al. reported
comparable findings in 41 men who underwent prostate
biopsies supplemented with cognitive-targeted biopsies
in suspicious regions based on prostate PHS. Targeted
biopsies were 4.5-fold more likely to be positive than
the random biopsies [11]. In our series, the rate of non-
significant cancers detected by PHS-targeted perineal
vs. systematic Bx was lower (Table 2). This rebuts po-
tential concerns of an increased detection of clinically
insignificant cancers caused by more substantial sam-
pling. PHS-targeted biopsies detected 6 significant pros-
tate cancers that were overseen by systematic biopsy.
Additionally, the absolute numbers of atypical histo-
pathological findings like ASAP, HG PIN and prostatitis
in PHS-positive sectors do not differ significantly from
systematic Bx despite the limited sampling.
Our data might suggest a reduction of biopsies in
non-PHS positive sectors and to focus on more vulner-
able or suspect regions in the prostate. The correspond-
ing PB scheme would theoretically achieve appropriate
sampling by targeting certain locations rather than by
increasing the core numbers. In an analysis of 164 aut-
opsies, which had not previously undergone clinical bi-
opsy, step-section analysis revealed that the common
12-core biopsy technique detects the majority of clinic-
ally significant cancers with a sensitivity of 80 % [15].
The authors conclude that the chance of detecting can-
cer was correlated more closely to the location of the
sampling (peripheral, lateral and apical cores) than to
the number of biopsy cores taken.
Prostate cancer detection rates from perineal targeted
biopsies differed from the transrectal targeted biopsy re-
gime. This difference occurred independently from pre-
vious tissue analysis, for the reason that both targeted
approaches are aligned to the same scanning process. In
comparison to the transrectal approach, the perinealbiopsy technique might reduce variables that can influ-
ence the needle placement. Furthermore, longitudinal bi-
opsy punches following the axis of the prostate seem to
allow more accurate sampling of the anterior part. The-
oretically, because previous studies reported inhomogen-
eous results comparing transrectal and transperineal
prostate biopsies [8, 16].
There are several limitations in this study. Firstly, the
analysis was performed on a regional basis. Dependen-
cies between neighboring regions, as well as correlation
of the different biopsy procedures with the HS results
are difficult to account for and may incur misleading re-
sults. Secondly, there is no minimum threshold defining
when a PHS signal is to be called positive; this may also
affect the results. For example, the targeted regions
could stretch across different sections meaning that even
a small amount in one sector would lead to it being seen
as a positive PHS sector, but it might still yield negative
biopsies because the few cores would not necessarily
pick up the cancer. Moreover, the knowledge of “abnor-
mal” regions might influence the surgeon’s decisions
during the subsequent systematic biopsy as a result of
the non-blinded, single-surgeon biopsy procedure.
Nevertheless, we did not find any significant inter-
operator variability with respect to the detection rate or
the biopsy approach.
Generally, it is difficult to compare the diagnostic ac-
curacy of Bx techniques in different patient series. Eth-
ical concerns will always prevent verification of negative
Bx results by radical prostatectomy, and positive biopsies
are not always and necessarily followed by prostatec-
tomy. Therefore, the clinical setting will always account
for a potential verification bias, not knowing what the
exact location of the cancer is and how many cancers
were missed by biopsy.
Finally, recent results from multi-parametric MRI pro-
cedures pull into question all ultrasound-based techniques
including color Doppler imaging, real-time elastography,
C-TRUS / ANNA and Prostate HS. The application of in-
tegrated interpretation strategies for mp MRI variables,
such as the PIRADS score, improves the risk stratification
for prostate cancer and allows for effective fusion guid-
ance of targeted prostate biopsy [17, 18]. Likewise, all
ultrasound modalities have been devised to increase the
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to visualize and locate tissues suspected of harboring pros-
tate cancer [19–21]. Despite their promising characteris-
tics, none of them are established in clinical practice
because of missing evidence, lack of standardization and
significant user-dependent performance. Similarity in
the prostate tissue features such as the degree of elasti-
city/firmness, irregular patterns of blood vessels and
ultrasound backscatter properties of malignant and
other non-malignant microstructures might account for
these limitations. So far, each technique in itselfis lim-
ited in its predictive impact on prostate cancer diagnos-
tics, but might be combined into an effective diagnostic
tool. Accordingly, a multiparametric approach similar to
MRI algorithms might improve future performance and
increase the diagnostic yield by specifically visualizing
and locating prostate cancer tissue.Conclusions
HS-augmented ultrasound analysis improves the inter-
pretation of transrectal prostate imaging by identifica-
tion of abnormal prostatic tissue. Although prostate
cancer specificity remains low, the additional informa-
tion facilitates improved biopsy targeting and results in a
higher cancer detection rate in selective prostate sectors.
The high NPV might help to reduce biopsies in PHS-
negative prostate sectors and to focus on more vulner-
able regions in the prostate. With the help of this
strategy, increased but unsought detection of clinically
insignificant cancers through too substantial sampling
can be avoided. The PHS technique should be consid-
ered at leastwith respect to patients who had previously
negative prostate biopsy results despite elevated PSA
levels. Further multicenter analysis has to confirm the
advantages of PHS in primary Bx-settings.
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